Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853467 | 0.91 | PRF1 (0.48) | HPGDS1PR4S1PR5 | |
| SCHEMBL1847859 | 0.90 | GPR52 (0.46) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL1850159 | 0.88 | GPR52 (0.54) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL1853392 | 0.88 | GPR52 (0.61) | GPR52S1PR4S1PR5KIFC1 | |
| SCHEMBL3215607 | 0.87 | TRPM8 (0.44) | GPR52S1PR4S1PR5 | |
| SCHEMBL1848608 | 0.87 | GPR52 (0.44) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL1848511 | 0.85 | GPR52 (0.45) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL3219547 | 0.84 | GPR52 (0.54) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL1852050 | 0.84 | GPR52 (0.47) | GPR52TP53POLBHPGDS1PR4 | |
| SCHEMBL1875707 | 0.84 | GPR52 (0.50) | GPR52TP53POLBHPGDS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885TP53 3403/4885POLB 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.